Combined treatment with a MEK inhibitor and the Bcl‐2 antagonist venetoclax was effective in chronic lymphocytic leukemia cells, independently of high‐risk prognostic markers. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.